Peripheral Vascular Diseases

5
Pipeline Programs
8
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
1
ABSOLUTE™: Self-Expandable Peripheral Nitinol StentPhase 41 trial
Treatment with CSI atherectomy deviceN/A1 trial
Active Trials
NCT03455374Terminated10Est. May 2019
NCT00180505Completed120Est. Oct 2009
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
SM-01Phase 31 trial
Active Trials
NCT01183117Completed105Est. Aug 2014
Bayer
BayerLEVERKUSEN, Germany
1 program
1
VasovistPhase 32 trials
Active Trials
NCT00483665Completed20
NCT00296855Completed261Est. Feb 2007
Design Therapeutics
1 program
1
Autologous Bone Marrow Mononuclear CellsPhase 1/21 trial
Active Trials
NCT00872326CompletedEst. May 2009
C
CordisFL - Miami Lakes
1 program
1
Sirolimus-Eluting BX Velocity Balloon-Expandable StentPhase 1/21 trial
Active Trials
NCT00489164Terminated83Est. May 2004
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Multispectral Optoacoustic TomographyN/A1 trial
Active Trials
NCT05110677Unknown9Est. Jul 2022
Bristol Myers Squibb
1 program
Screening DIVA - Diffuse Vascular DiseaseN/A
Sanofi
SanofiPARIS, France
1 program
Screening DIVA - Diffuse Vascular DiseaseN/A1 trial
Active Trials
NCT01076738Completed2,233Est. Jun 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottABSOLUTE™: Self-Expandable Peripheral Nitinol Stent
Johnson & JohnsonSM-01
BayerVasovist
Design TherapeuticsAutologous Bone Marrow Mononuclear Cells
CordisSirolimus-Eluting BX Velocity Balloon-Expandable Stent
Heidelberg PharmaMultispectral Optoacoustic Tomography
AbbottTreatment with CSI atherectomy device
SanofiScreening DIVA - Diffuse Vascular Disease
BayerVasovist

Clinical Trials (9)

Total enrollment: 2,841 patients across 9 trials

NCT00180505AbbottABSOLUTE™: Self-Expandable Peripheral Nitinol Stent

ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries

Start: Mar 2005Est. completion: Oct 2009120 patients
Phase 4Completed
NCT01183117Johnson & JohnsonSM-01

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Start: Jul 2010Est. completion: Aug 2014105 patients
Phase 3Completed
NCT00296855BayerVasovist

Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease

Start: Feb 2006Est. completion: Feb 2007261 patients
Phase 3Completed
NCT00872326Design TherapeuticsAutologous Bone Marrow Mononuclear Cells

Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia

Start: Dec 2007Est. completion: May 2009
Phase 1/2Completed
NCT00489164CordisSirolimus-Eluting BX Velocity Balloon-Expandable Stent

Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions

Start: Aug 2002Est. completion: May 200483 patients
Phase 1/2Terminated
NCT05110677Heidelberg PharmaMultispectral Optoacoustic Tomography

Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images

Start: Nov 2021Est. completion: Jul 20229 patients
N/AUnknown
NCT03455374AbbottTreatment with CSI atherectomy device

Diamondback in Peripheral Vascular Disease

Start: Aug 2017Est. completion: May 201910 patients
N/ATerminated
NCT01076738SanofiScreening DIVA - Diffuse Vascular Disease

Screening DIVA - Diffuse Vascular Disease

Start: Apr 2009Est. completion: Jun 20102,233 patients
N/ACompleted
NCT00483665BayerVasovist

Vasovist Endoleak Study

Start: Jun 200620 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space